PDE4 inhibitors exhibit potent anti-inflammatory action and have been recognized as the novel therapeutic approach to treat severe chronic obstructive pulmonary disease (COPD) and asthma (7). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.